Shares Magazine
59.93p+2.73 (+4.78%)02 Oct 2024, 12:12
Jump to:
Novacyt S.A. Fundamentals
| Company Name | Novacyt S.A. | Last Updated | 2024-10-02 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 70.626 m | Market Cap | £42.33 m |
| PE Ratio | 1.19 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.40 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.1322 | Debt Equity Ratio | 0.1675 |
| Asset Equity Ratio | 1.4117 | Cash Equity Ratio | 0.4679 |
| Quick Ratio | 2.6831 | Current Ratio | 4.04 |
| Price To Book Value | 0.5737 | ROCE | 0 |
Novacyt S.A. Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Novacyt S.A. Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £15.22 m | £3.27 m | £6.38 m |
| Intangible Assets | £31.68 m | £9.77 m | £15.18 m |
| Investments | £57,000.00 | 0 | £144,000.00 |
| Total Fixed Assets | £47.37 m | £13.66 m | £24.91 m |
| Stocks | £3.02 m | £3.03 m | £11.46 m |
| Debtors | £27.49 m | £25.35 m | £30.29 m |
| Cash & Equivalents | £44.06 m | £86.98 m | £101.75 m |
| Other Assets | £413,000.00 | £624,000.00 | £3.21 m |
| Total Assets | £133.81 m | £140.90 m | £183.70 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £29.57 m | £24.24 m | £38.90 m |
| Creditors after 1 year | £17.01 m | £1.45 m | £2.98 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £46.57 m | £25.68 m | £41.88 m |
| Net assets | £87.24 m | £115.22 m | £141.81 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £4.05 m | £4.05 m | £4.05 m |
| Share Premium | £50.67 m | £50.67 m | £50.67 m |
| Profit / Loss | -£28.57 m | -£20.05 m | -£5.66 m |
| Other Equity | £87.24 m | £115.22 m | £141.81 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £87.24 m | £115.22 m | £141.81 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.13 | £0.00 | £0.01 |
| Debt-to-Equity | £0.14 | £0.00 | £0.01 |
| Assets / Equity | 1.4117 | 1.4117 | 1.4117 |
| Cash / Equity | 0.4679 | 0.4679 | 0.4679 |
| EPS | -£0.32 | -£0.30 | -£0.09 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£24.99 m | -£13.73 m | £15.69 m |
| Cashflow before financing | -£28.96 m | -£14.24 m | £15.05 m |
| Increase in Cash | -£42.89 m | -£14.82 m | £10.06 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £11.58 m | £21.04 m | £92.60 m |
| Cost of sales | £7.85 m | £15.29 m | £64.38 m |
| Gross Profit | £3.73 m | £5.75 m | £28.23 m |
| Operating Profit | -£29.52 m | -£23.39 m | -£3.92 m |
| Pre-Tax profit | -£28.57 m | -£20.05 m | -£5.66 m |
Novacyt S.A. Company Background
| Sector | Healthcare |
|---|---|
| Activities | Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment. |
| Latest Interim Date | 26 Sep 2024 |
| Latest Fiscal Year End Date | 30 May 2024 |
Novacyt S.A. Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-07-29 | Mr. Graham D. Mullis | Executive Director,Chief Executive Officer |
| 2024-04-30 | Dr. Andrew John William Heath | Non-Executive Director,Senior Independent Director |
| 2022-12-07 | Dr. Edwin Snape | Non-Executive Director |
| 2023-05-26 | Mr. Anthony Stephen Dyer | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-10-01 | Mr. James Christopher Wakefield | Non-Executive Director,Chairman |
| 2024-06-14 | Mr. Jean-Pierre Jacques Crinelli | Non-Executive Director |
| 2024-05-01 | Mr. Lyn Dafydd Rees | Executive Director,Chief Executive Officer |
| 2024-05-01 | Dr. Joanne Nicola Mason | Executive Director,Chief Scientific Officer |
| 2024-06-14 | Mr. James McCarthy | Executive Director,Interim Chief Executive Officer and Chief Financial Officer |
| 2022-11-10 | Mr. David James Allmond | Executive Director,Chief Executive Officer |
| 2024-05-01 | Mr. Steven Michael Gibson | Executive Director,Chief Financial Officer |
Novacyt S.A. Contact Details
| Company Name | Novacyt SA |
|---|---|
| Address | 13, Avenue Morane Saulnier, Velizy-Villacoublay, 78140 |
| Telephone | +33 139465104 |
| Website | https://www.novacyt.com |
Novacyt S.A. Advisors
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Fidelity China Special Situations PLC | 239.08 | 6.97 |
| Ithaca Energy PLC | 112.80 | 4.83 |
| Prudential PLC | 716.00 | 3.53 |
| Schroder Asiapacific Fund PLC | 562.00 | 2.74 |
| Harbour Energy PLC | 278.60 | 2.69 |
| Schroder Oriental Income Fund Limited | 280.94 | 2.53 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Wizz Air Holdings PLC | 1,284.00 | -6.07 |
| Jd Sports Fashion PLC | 141.45 | -5.38 |
| Aston Martin Lagonda Global Holdings PLC | 110.89 | -5.38 |
| Close Brothers Group PLC | 383.84 | -4.66 |
| Severn Trent PLC | 2,606.00 | -3.12 |
| Ocado Group PLC | 383.20 | -2.79 |